NCT04414475 2026-02-02
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Karyopharm Therapeutics Inc
Phase 2 Recruiting
Clinical Trials
15 trialsNCT02227251 2025-10-01
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 2 Recruiting
NCT03992339 2025-02-07
SEARCH
Antengene Corporation
Phase 2 Completed
NCT04782687 2025-01-16
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
US Oncology Research
Phase 2 Active not recruiting
NCT04768881 2024-08-23
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT04854434 2023-11-03
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT03944057 2023-06-15
MARCH
Antengene Corporation
Phase 2 Completed
NCT01986348 2023-01-26
KING
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT02025985 2023-01-26
SIGN
Karyopharm Therapeutics Inc
Phase 2 Completed
NCT02138786 2023-01-26
SIRRT
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT02146833 2023-01-26
SHIP
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT02213133 2023-01-26
STARRS
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT02314247 2023-01-26
Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT02336815 2023-01-26
STORM
Karyopharm Therapeutics Inc
Phase 2 Completed
NCT02628704 2023-01-26
SCORE
Karyopharm Therapeutics Inc
Phase 2 Withdrawn